Indefinite Delivery Contract SPE2DR25D9316

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC is part of the DLA's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple Prime Vendor Contracts to provide worldwide pharmaceutical support to the Defense Health Agency, Department of Defense, United States Coast Guard, and other government agencies. The unrestricted, fully competitive solicitation is expected to be issued in March 2024 and will remain open for 45 days, with the intent to make multiple regional awards to ensure the Department of Defense's resiliency and access to vital pharmaceuticals during contingencies or natural disasters.